The Genomics Core provides consultation and state-of-the-art genomic technologies to KCI investigators. Core scientists interact with KCI researchers to design experiments, generate preliminary data, write methodologies, and generate and analyze experimental data. The Core supports research investigating genetic factors: a) responsible for cancer susceptibility, b) involved in neoplastic initiation and progression, and c) affecting cancer treatment. Existing Core technologies include: 1) nucleic acid isolation (Qiagen TissueLyser, AutoPure and EZ1 Advanced); 2) DNA sequencing (Applied Biosystems 3730 and 3100); 3) genotyping (Applied Biosystems 7900, lllumina iScan, and Affymetrix GeneChip System); 4) expression analysis (Applied Biosystems 7900, lllumina iScan, and Affymetrix GeneChip System);and 5) Next Generation Sequencing (lllumina Genome Analyzer NX with paired-end module).

Public Health Relevance

The Genomics Core supports research investigating genetic factors responsible for cancer susceptibility involved in neoplastic initiation and progression, and affecting cancer treatment using high-throughput technologies in a cost-effective manner.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA022453-32
Application #
8600863
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
32
Fiscal Year
2014
Total Cost
$390,759
Indirect Cost
$133,678
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Ratanatharathorn, V; Deol, A; Ayash, L et al. (2015) Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT. Bone Marrow Transplant 50:106-12
Bollig-Fischer, Aliccia; Chen, Wei; Gadgeel, Shirish M et al. (2015) Racial diversity of actionable mutations in non-small cell lung cancer. J Thorac Oncol 10:250-5
Motzer, Robert J; Rini, Brian I; McDermott, David F et al. (2015) Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol 33:1430-7
Wijesinghe, Priyanga; Bepler, Gerold; Bollig-Fischer, Aliccia (2015) A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer. J Thorac Oncol 10:381-6
Koo, Imhoi; Yao, Sen; Zhang, Xiang et al. (2014) Comparative analysis of false discovery rate methods in constructing metabolic association networks. J Bioinform Comput Biol 12:1450018
Koo, Imhoi; Wei, Xiaoli; Shi, Xue et al. (2014) Constructing Metabolic Association Networks Using High-dimensional Mass Spectrometry Data. Chemometr Intell Lab Syst 138:193-202
Heng, D Y C; Choueiri, T K; Rini, B I et al. (2014) Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol 25:149-54
Szalai, Gabor; Xu, Yi; Romero, Roberto et al. (2014) In vivo experiments reveal the good, the bad and the ugly faces of sFlt-1 in pregnancy. PLoS One 9:e110867
Bengsch, F; Buck, A; Gunther, S C et al. (2014) Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression. Oncogene 33:4474-84
Speyer, Cecilia L; Hachem, Ali H; Assi, Ali A et al. (2014) Metabotropic glutamate receptor-1 as a novel target for the antiangiogenic treatment of breast cancer. PLoS One 9:e88830

Showing the most recent 10 out of 321 publications